Small Fiber Neuropathy
Small fiber neuropathy (SFN) is a condition in which the thin, unmyelinated C-fibers and lightly myelinated A-delta fibers that carry pain, temperature, and autonomic signals are selectively damaged, while the larger nerve fibers that control motor function and are measured by standard nerve conduction studies remain intact. This makes SFN notoriously difficult to diagnose through conventional testing, leaving many patients undiagnosed for years despite severe, disabling symptoms. The condition affects people of all ages, including younger adults and even children, and has a wide range of underlying causes. Identifying and treating the underlying cause is the most important step in halting progression.
Symptoms
- burning or stinging pain, often in the feet and lower legs
- allodynia — pain from stimuli that should not be painful, such as light touch or bed sheets
- reduced ability to sense temperature or pain in affected areas
- dry eyes or dry mouth from autonomic involvement
- orthostatic hypotension — lightheadedness when standing up
- abnormal sweating — either excessive or reduced
- rapid heart rate or palpitations
- gastrointestinal symptoms such as nausea, bloating, or constipation
Causes
- diabetes or pre-diabetes — even borderline blood sugar elevations can damage small fibers
- autoimmune conditions such as Sjogren’s syndrome, lupus, or sarcoidosis
- genetic mutations — SCN9A and SCN10A sodium channel gene variants are found in a subset of patients
- idiopathic — no identifiable cause found in up to 50 percent of cases
- vitamin B12 deficiency or excess vitamin B6
- celiac disease and other systemic inflammatory conditions
How It Progresses
SFN progression varies widely depending on the underlying cause. When an identifiable trigger such as pre-diabetes, Sjogren’s syndrome, or celiac disease is found and treated, symptoms may stabilize or even partially improve. In idiopathic cases, the course is less predictable — some patients remain stable for years, while others experience gradual worsening.
Because small fibers regulate both sensory and autonomic functions, advanced SFN can affect multiple body systems simultaneously. Patients may develop gastrointestinal dysmotility, abnormal blood pressure regulation, urinary dysfunction, or sexual dysfunction as autonomic small fibers are progressively damaged. These systemic effects can be as disabling as the pain itself.
Early diagnosis and thorough investigation for underlying causes offers the best chance of modifying the disease course. Patients with confirmed autoimmune-mediated SFN may benefit from immunomodulatory treatments — a direction that requires evaluation by a neuromuscular specialist or rheumatologist.
Diagnosis
Standard nerve conduction studies (NCV/EMG) are typically normal in SFN because they only assess large nerve fibers. The gold standard for diagnosis is a skin punch biopsy — a small, minimally invasive procedure in which a few millimeters of skin are removed from the calf and ankle, then analyzed under a microscope to count intraepidermal nerve fiber density. A density below the fifth percentile for age and sex confirms the diagnosis.
The autonomic QSART (quantitative sudomotor axon reflex test) measures sweat gland function and can detect autonomic small fiber involvement even when skin biopsy is borderline. Corneal confocal microscopy, which images small nerve fibers in the cornea non-invasively, is an emerging tool available at specialized centers.
Once SFN is confirmed, an extensive workup for underlying causes is essential, including glucose tolerance testing, autoimmune panels, genetic testing in appropriate candidates, and evaluation for systemic diseases. Many patients receive the correct diagnosis only after seeing multiple specialists.
Conventional Treatments
Treatment targets both the underlying cause (if identified) and symptom management. For autoimmune-mediated SFN, intravenous immunoglobulin (IVIg) has shown benefit in some studies and is increasingly used for confirmed autoimmune cases. Treating underlying pre-diabetes through lifestyle modification may slow fiber loss.
For pain, the same agents used in diabetic neuropathy — duloxetine, pregabalin, gabapentin, low-dose tricyclics — are often tried, though response rates in SFN can be more variable. Topical lidocaine, capsaicin 8% patch (Qutenza, applied in a clinical setting), and low-dose naltrexone are additional options some specialists use. Sodium channel blockers such as mexiletine are under investigation given the role of sodium channel gene variants in some patients.
Non-pharmacological approaches including low-level laser therapy, TENS, and graded exercise therapy may help reduce pain and improve autonomic stability. Consult a neurologist experienced with SFN before starting any new treatment regimen.
When to See a Specialist
If you have chronic burning pain, allodynia, or autonomic symptoms and standard neuropathy workups have returned normal, specifically request evaluation for small fiber neuropathy at a neuromuscular or neuropathy clinic. Access to skin punch biopsy is the critical diagnostic step, and not all general neurology practices perform this test routinely.
Patients with rapidly worsening symptoms, evidence of autonomic dysfunction affecting heart rate or blood pressure, or those who have not responded to multiple pain medications benefit most from referral to an academic medical center with a dedicated autonomic or neuromuscular program.
Related Treatments
tens-therapy
physical-therapy-neuropathy
Frequently Asked Questions
Can small fiber neuropathy be cured?
When an underlying cause is identified and treated — such as controlling blood sugar, treating Sjogren’s syndrome, or eliminating gluten in celiac disease — some patients experience partial to significant improvement in symptoms and even partial nerve fiber regeneration on repeat skin biopsy. For idiopathic SFN, the goal is symptom control and preventing progression rather than cure.
Why does my nerve conduction test come back normal if I have so much pain?
Standard nerve conduction tests only measure large myelinated nerve fibers. Small fiber neuropathy selectively damages the thin fibers that carry pain and temperature signals, which are not captured by standard electrodiagnostic studies. A skin punch biopsy is required to directly visualize and count the affected small nerve fibers.
Is small fiber neuropathy an autoimmune disease?
In a significant subset of patients, yes. Studies have found elevated autoantibodies — including against trisulfated heparin disaccharide (TS-HDS) and fibroblast growth factor receptor 3 (FGFR3) — in SFN patients, suggesting immune-mediated mechanisms. This is an active area of research and has important treatment implications, as these patients may respond to IVIg or other immunomodulatory therapies.
Is small fiber neuropathy progressive?
It can be, particularly if an underlying cause is not identified and treated. However, progression varies considerably. Some patients remain stable for years, and those who respond to treatment of an underlying cause may actually show improvement on repeat skin biopsy. Regular follow-up with your neurologist and periodic repeat biopsies are reasonable to monitor the course.